Santyl ointment costs roughly $333 for a 30-gram tube and over $936 for 90 grams at retail, making it one of the pricier topical medications you can encounter. Several factors drive that price: it’s a biologic product derived from living bacteria, it has no generic competition, and a single company controls the entire market.
What Santyl Does and Why It Matters
Santyl contains an enzyme called collagenase, which is harvested from a specific strain of bacteria (Clostridium histolyticum). When applied to a wound, the enzyme selectively breaks down dead tissue while leaving healthy tissue intact. This process, called enzymatic debridement, is used to clean chronic wounds like pressure ulcers, diabetic foot ulcers, and burns so they can heal properly.
The alternative to enzymatic debridement is often surgical debridement, where a clinician physically cuts away dead tissue, or autolytic methods that use moisture-retaining dressings to let the body dissolve dead tissue on its own. Santyl fills a niche for patients who need active debridement but aren’t good candidates for a surgical procedure, or for wounds that need ongoing maintenance between clinic visits.
It’s a Biologic, Not a Simple Chemical
Most topical ointments contain synthetic chemicals that can be manufactured in bulk through straightforward chemical processes. Santyl is fundamentally different. Its active ingredient is a protein enzyme produced by living bacteria, which must be cultured, harvested, purified, and stabilized while maintaining the enzyme’s biological activity. This type of manufacturing is closer to how vaccines or injectable biologics are made than how a typical cream is produced.
Biologic manufacturing requires tightly controlled fermentation conditions, specialized purification steps, and extensive quality testing to ensure each batch has consistent potency. If the enzyme degrades or loses activity at any point, the product is useless. These requirements make production significantly more expensive than synthesizing a standard drug compound, and that cost gets passed directly to the consumer.
No Generic Competition Exists
Santyl is the only FDA-approved collagenase ointment on the U.S. market. It’s manufactured exclusively by Smith & Nephew, giving the company complete pricing control. Unlike common medications where multiple generic manufacturers compete and drive prices down, Santyl operates as a monopoly product.
Creating a generic version of a biologic is far harder than copying a pill. Generic biologics (called biosimilars) require manufacturers to demonstrate that their product is functionally equivalent to the original, which means replicating a complex biological manufacturing process rather than just matching a chemical formula. The relatively small market for wound debridement ointments likely discourages competitors from investing the tens of millions needed to develop, test, and seek approval for a biosimilar. Smith & Nephew reported “mid-single digit growth” from Santyl sales in 2025, suggesting steady but not blockbuster revenue, the kind of market that doesn’t attract aggressive generic competition.
How the Weekly Cost Compares to Alternatives
At a wholesale acquisition cost of about $6.83 per gram, treating an average-sized wound (roughly 7.8 square centimeters) with Santyl runs approximately $63.75 per week. By comparison, medicinal honey, an autolytic debridement alternative, costs around $3.60 per week for the same wound size. On a per-week basis, Santyl costs nearly 18 times more than honey-based products.
That sticker shock, however, doesn’t tell the full story. A Medicare-focused economic analysis found that over one year, patients treated with Santyl had total care costs of $6,161 compared to $7,149 for those treated with medicinal honey. The reason: Santyl-treated wounds tended to heal faster, which meant fewer clinic visits, fewer dressing changes, and less overall care. The study estimated that for every 1% of patients shifted from medicinal honey to Santyl, payers saved nearly $9,900 per year across a group of 1,000 patients. Separate analyses have also found Santyl cost-effective compared to hydrocolloid and hydrogel dressings.
So while the tube itself is expensive, the total cost of wound care (including nursing time, supplies, and complications from slow healing) can actually be lower with Santyl. This is part of how Smith & Nephew justifies the price to insurers and Medicare.
What You’re Actually Paying
Your out-of-pocket cost depends heavily on your insurance. Medicare Part B often covers Santyl when it’s applied during an outpatient wound care visit, and some Medicare Part D plans cover it for home use. Private insurers vary widely. Some require prior authorization, others place it on a high-cost specialty tier, and some exclude it entirely.
Without insurance, you’re looking at $333 or more for a single 30-gram tube, which may last one to three weeks depending on wound size. A 90-gram tube at roughly $936 is slightly cheaper per gram ($10.40 versus $11.12) but still a significant expense. Smith & Nephew does offer a patient assistance program, and pharmacy discount cards can sometimes reduce the price, though savings vary.
Why the Price Keeps Climbing
Santyl’s price has increased steadily over the years, a pattern common with monopoly pharmaceuticals in the U.S. Without generic competitors to create downward pressure, and with consistent demand from wound care clinics and nursing homes, there’s little market incentive for Smith & Nephew to lower the price. The aging U.S. population means more chronic wounds, more demand for debridement products, and a reliable customer base that has few other enzymatic options. As long as insurers and Medicare continue to cover Santyl and no competitor enters the market, the price is unlikely to drop.